For the current week, the overall ratings of seven Biotechnology stocks are worse, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health (NASDAQ:GHDX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price has fallen 7.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of June 26, 2013, 10.1% of outstanding Genomic Health shares were held short. The stock’s trailing PE Ratio is 171.20. For more information, get Portfolio Grader’s complete analysis of GHDX stock.
This week, Acorda Therapeutics (NASDAQ:ACOR) drops from a C to a D rating. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.
Amarin (NASDAQ:AMRN) earns a D this week, falling from last week’s grade of C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of June 26, 2013, 16.6% of outstanding Amarin shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.
Exelixis’ (NASDAQ:EXEL) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of June 26, 2013, 18.8% of outstanding Exelixis shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.
Trius Therapeutics (NASDAQ:TSRX) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader.
The rating of Discovery Laboratories (NASDAQ:DSCO) slips from a C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
This week, Achillion’s (NASDAQ:ACHN) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. As of June 26, 2013, 13.3% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.